UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50
MLV reiterated its Buy rating on Novavax (NASDAQ: NVAX). At the same time, the rating agency reduced its price target on the company's stock from $11 to $9.50. On Thursday, NVAX closed the day at $1.33.







